Lessons from gefitinib-induced interstitial lung disease in Japan: Problems in approval, pharmacovigilance, and regulatory decision-making procedures
暂无分享,去创建一个
Masanori Fukushima | Shigeyuki Matsui | Satoshi Teramukai | Masatsugu Nakagawa | Tsutomu Nishimura | Harue Tada | S. Matsui | S. Teramukai | H. Tada | Tsutomu Nishimura | M. Fukushima | M. Nakagawa
[1] M. Fukushima. The overdose of drugs in Japan , 1989, Nature.
[2] Renato Martins,et al. Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.
[3] A. Ruigómez. Pharmacoepidemiology: an introduction. 3rd edn. , 2002 .
[4] S. Kudoh,et al. Interstitial lung disease associated with drug therapy , 2004, British Journal of Cancer.
[5] M. Ebina,et al. Severe acute interstitial pneumonia and gefitinib , 2003, The Lancet.
[6] Peter Jüni,et al. Lessons from the withdrawal of rofecoxib , 2004, BMJ : British Medical Journal.
[7] David C. Anderson,et al. Harrison’s Principles of Internal Medicine, 16th Edition , 2005, Neurology.
[8] Masanori Fukushima Tokyo. Clinical trials in Japan , 1995, Nature Medicine.
[9] Kevin Carroll,et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) , 2005, The Lancet.
[10] P. Camus. Interstitial lung disease in patients with non-small-cell lung cancer: causes, mechanisms and management , 2004, British Journal of Cancer.
[11] P. Foucher,et al. Interstitial Lung Disease Induced by Drugs and Radiation , 2004, Respiration.
[12] T. Evans. Highlights from the Tenth World Conference on Lung Cancer. , 2004, The oncologist.
[13] R. Pazdur,et al. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. , 2003, The oncologist.
[14] T. Čufer,et al. Results from a phase II, open-label, randomized study (SIGN) comparing gefitinib with docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer , 2005 .
[15] K. Kiura,et al. Interstitial lung disease (ILD) during gefitinib treatment in Japanese patients with non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group , 2004 .
[16] Takayuki Kosaka,et al. Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer , 2004, Cancer Research.
[17] Takayuki Kosaka,et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Anthony S. Fauci,et al. HARRISON'S PRINCIPLES OF INTERNAL MEDICINE, 13TH EDITION: , 2004 .
[19] H. Wada,et al. Hypoalbuminemia as a risk factor of interstitial lung disease (ILD) during gefitinib treatment in patients with non-small cell lung cancer (NSCLC): A JMTO study , 2005 .
[20] Masahiro Fukuoka,et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] M. Kusumoto,et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. , 2004, Lung cancer.
[22] N. Yamamoto,et al. Interstitial lung diseases (ILD) induced by gefitinib in patients with advanced non-small cell lung cancer (NSCLC): Results of a West Japan Thoracic Oncology Group (WJTOG) epidemiological survey. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] M. Fukuoka,et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] J. Minna,et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.
[25] A. Lundberg,et al. Interstitial lung disease following erlotinib (Tarceva®) in a patient who previously tolerated gefitinib (Iressa®) , 2005, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[26] Richard Horton,et al. Vioxx, the implosion of Merck, and aftershocks at the FDA , 2004, The Lancet.
[27] J. Bigby. Harrison's Principles of Internal Medicine , 1988 .
[28] K. Aoshiba,et al. Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis. , 2003, Cancer research.
[29] M. Fukuoka,et al. Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer. , 2004, Lung cancer.
[30] S. Shapiro. Pharmacoepidemiology: An Introduction , 1998, Annals of Internal Medicine.